Medicinova (MNOV) Depreciation & Amortization (CF) (2010 - 2025)
Medicinova (MNOV) posted quarterly Depreciation & Amortization (CF) of $4555.0 for Q4 2025, down 12.01% year-over-year from $5177.0 in Q4 2024, and down 14.11% quarter-over-quarter from $5303.0 in Q3 2025.
Medicinova (MNOV) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
Medicinova (MNOV) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $4555.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 12.01% year-over-year to $4555.0; the TTM figure through Dec 2025 stood at $20099.0 (down 4.64% YoY), while the FY2025 annual figure was $20099.0, down 4.64% from the prior year.
- Depreciation & Amortization (CF) retreated to $4555.0 in Q4 2025 per MNOV's latest filing, from $5303.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $7168.0 in Q3 2021 and bottomed at $4105.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $5266.4 across 5 years, with a median of $5178.5 in 2024.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 37.4% — and 2022, when it slumped 37.79%.
- Medicinova's Depreciation & Amortization (CF) stood at $6374.0 in 2021, then slumped by 32.05% to $4331.0 in 2022, then rose by 26.81% to $5492.0 in 2023, then decreased by 5.74% to $5177.0 in 2024, then declined by 12.01% to $4555.0 in 2025.
- Business Quant data shows MNOV's Depreciation & Amortization (CF) at $4555.0 in Q4 2025, $5303.0 in Q3 2025, and $5064.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,555.00 |
| Dec 31, 2025 | 4,555.00 |
| Sep 30, 2025 | 5,303.00 |
| Sep 30, 2025 | 5,303.00 |
| Jun 30, 2025 | 5,064.00 |
| Jun 30, 2025 | 5,064.00 |
| Mar 31, 2025 | 5,177.00 |
| Mar 31, 2025 | 5,177.00 |
| Dec 31, 2024 | 5,177.00 |
| Dec 31, 2024 | 5,177.00 |
| Sep 30, 2024 | 5,180.00 |
| Sep 30, 2024 | 5,180.00 |
| Jun 30, 2024 | 5,370.00 |
| Jun 30, 2024 | 5,370.00 |
| Mar 31, 2024 | 5,350.00 |
| Mar 31, 2024 | 5,350.00 |
| Dec 31, 2023 | 5,492.00 |
| Dec 31, 2023 | 5,492.00 |
| Sep 30, 2023 | 5,703.00 |
| Sep 30, 2023 | 5,703.00 |